Stock Track | Eli Lilly Soars 10.12% Intraday on Strong Q4 Earnings Beat and Upbeat 2026 Guidance for Weight-Loss Drugs

Stock Track

Feb 04

Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.

The sharp rise follows the company's release of fourth-quarter 2025 financial results that substantially exceeded analyst expectations, with adjusted earnings per share of $7.54 beating estimates of $6.67 and revenue of $19.29 billion surpassing the $17.96 billion consensus.

Investors responded enthusiastically to Eli Lilly's optimistic 2026 guidance, which projects adjusted EPS of $33.50 to $35.00 and revenue of $80 billion to $83 billion, both above market forecasts, driven by soaring demand for weight-loss medications Zepbound and Mounjaro.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1161501977"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161501977\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161501977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161501977","market":"sg","top_or_hot":-1,"title":"Stock Track | Eli Lilly Soars 10.12% Intraday on Strong Q4 Earnings Beat and Upbeat 2026 Guidance for Weight-Loss Drugs","media":"Stock Track","content":"<p>Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.</p><p>The sharp rise follows the company's release of fourth-quarter 2025 financial results that substantially exceeded analyst expectations, with adjusted earnings per share of $7.54 beating estimates of $6.67 and revenue of $19.29 billion surpassing the $17.96 billion consensus.</p><p>Investors responded enthusiastically to Eli Lilly's optimistic 2026 guidance, which projects adjusted EPS of $33.50 to $35.00 and revenue of $80 billion to $83 billion, both above market forecasts, driven by soaring demand for weight-loss medications Zepbound and Mounjaro.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Soars 10.12% Intraday on Strong Q4 Earnings Beat and Upbeat 2026 Guidance for Weight-Loss Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Soars 10.12% Intraday on Strong Q4 Earnings Beat and Upbeat 2026 Guidance for Weight-Loss Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.</p><p>The sharp rise follows the company's release of fourth-quarter 2025 financial results that substantially exceeded analyst expectations, with adjusted earnings per share of $7.54 beating estimates of $6.67 and revenue of $19.29 billion surpassing the $17.96 billion consensus.</p><p>Investors responded enthusiastically to Eli Lilly's optimistic 2026 guidance, which projects adjusted EPS of $33.50 to $35.00 and revenue of $80 billion to $83 billion, both above market forecasts, driven by soaring demand for weight-loss medications Zepbound and Mounjaro.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1161501977","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161501977","pubTimestamp":1770220639,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.The sharp rise follows the company's release of fourth-quarter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"个股追踪|礼来盘中大涨10.12%，Q4盈利强劲，2026年减肥药指引乐观","themeId":"bcb73b9a2718796b6bdfcc143da1014d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.The sharp rise follows the company's release of fourth-quarter 2025 financial results that substantially exceeded analyst expectations, with adjusted earnings per share of $7.54 beating estimates of $6.67 and revenue of $19.29 billion surpassing the $17.96 billion consensus.Investors responded enthusiastically to Eli Lilly's optimistic 2026 guidance, which projects adjusted EPS of $33.50 to $35.00 and revenue of $80 billion to $83 billion, both above market forecasts, driven by soaring demand for weight-loss medications Zepbound and Mounjaro.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}